Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Goodwill & Intangibles (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Goodwill & Intangibles for 15 consecutive years, with $282.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Goodwill & Intangibles rose 866.06% to $282.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $282.4 million, a 866.06% increase, with the full-year FY2024 number at $296.0 million, up 529.49% from a year prior.
  • Goodwill & Intangibles was $282.4 million for Q3 2025 at Usana Health Sciences, up from $142.6 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $296.0 million in Q4 2024 to a low of $29.2 million in Q3 2024.
  • A 5-year average of $87.2 million and a median of $47.9 million in 2021 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: crashed 36.8% in 2024, then soared 866.06% in 2025.
  • Usana Health Sciences' Goodwill & Intangibles stood at $47.8 million in 2021, then rose by 4.14% to $49.8 million in 2022, then decreased by 5.58% to $47.0 million in 2023, then skyrocketed by 529.49% to $296.0 million in 2024, then fell by 4.58% to $282.4 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Goodwill & Intangibles are $282.4 million (Q3 2025), $142.6 million (Q2 2025), and $291.4 million (Q1 2025).